What is the Dupixent MDL? [2026 Guide]

The U.S. Judicial Panel on Multidistrict Litigation created the Dupixent MDL on June 4, 2026, after determining that federal lawsuits involving Dupixent and cutaneous T-cell lymphoma shared common factual questions.

The proceeding is formally titled In re: Dupixent (Dupilumab) Products Liability Litigation, MDL No. 3180, and is pending in the U.S. District Court for the District of New Jersey.

The cases have been assigned to U.S. District Judge Zahid N. Quraishi for coordinated pretrial proceedings.

When the transfer order was entered, the litigation included 15 filed actions and seven potential tag-along cases spread across 12 federal districts.

Many plaintiffs were patients receiving dupilumab therapy for severe atopic dermatitis, while others included asthma patients and people treated for additional inflammatory conditions.

The lawsuits allege that some users developed CTCL after starting Dupixent, while others had preexisting or undiagnosed lymphoma that progressed during treatment.

The litigation will examine CTCL compared to atopic dermatitis, including whether overlapping skin symptoms caused lymphoma to be mistaken for eczema before patients received a biopsy or specialist evaluation.

The court will also address evidence concerning lymphoma risk and potential mechanism, the manufacturers’ knowledge of reported cases, and the warnings provided to doctors and patients.

The allegations raised across the centralized lawsuits include:

• Dupixent caused or contributed to the development of cutaneous T-cell lymphoma in certain users.
• Dupixent accelerated the progression of preexisting or undiagnosed CTCL.
• Early CTCL symptoms were misidentified as eczema or severe atopic dermatitis before patients began treatment.
• Sanofi, Regeneron, and Genzyme knew or should have known about reports linking dupilumab use to CTCL.
• The manufacturers failed to provide adequate warnings about the alleged lymphoma risk.
• Dupixent’s effects on IL-4 and IL-13 signaling may create a biological pathway that promotes or unmasks malignant T-cell activity.
• Doctors and patients were not given sufficient information to evaluate persistent, worsening, or atypical skin symptoms during treatment.
• Delayed biopsies and lymphoma diagnoses allowed some patients’ disease to progress before appropriate cancer treatment began.
• The manufacturers continued to market Dupixent without adding warnings that plaintiffs claim were supported by medical literature and adverse event reports.

Centralization allows Judge Quraishi to oversee shared discovery concerning Dupixent’s development, safety monitoring, reported CTCL cases, corporate communications, and warning decisions.

The MDL does not establish that Dupixent causes lymphoma or resolve whether any individual plaintiff is entitled to compensation.

Each claimant must still present evidence connecting Dupixent use to the diagnosis, progression, and resulting damages alleged in the individual lawsuit.

What is Multidistrict Litigation (MDL)?

Multidistrict litigation, or MDL, is a federal court process used to coordinate lawsuits that involve common factual questions.

The U.S. Judicial Panel on Multidistrict Litigation may transfer those cases to one federal judge for shared pretrial proceedings.

The assigned court can oversee document production, depositions, expert discovery, motions, and other issues that would otherwise be repeated across multiple districts.

Each plaintiff keeps an individual lawsuit based on their own medical history, alleged injuries, and damages.

Cases that do not settle or resolve during the coordinated proceedings may later return to their original federal courts for trial.

MDL proceedings are frequently used in pharmaceutical and medical product litigation involving common evidence about product design, safety warnings, corporate conduct, and scientific causation.

Is there a Dupixent Class Action Lawsuit?

There is no Dupixent class action lawsuit, but federal Dupixent claims have been consolidated in multidistrict litigation known as MDL No. 3180.

A class action allows one or more representatives to pursue claims on behalf of a larger group, while an MDL coordinates separate lawsuits that share common factual and legal issues.

Each person in the Dupixent MDL keeps an individual claim and must establish their own treatment history, CTCL diagnosis, causation, damages, and eligibility for compensation.

The federal court can address shared discovery, expert testimony, corporate records, and warning allegations without deciding every plaintiff’s case at once.

Lawsuits that do not settle or resolve during the MDL may later return to their original federal courts for individual trials.

Scientific evidence has become a central issue in the Dupixent lawsuits because the parties dispute whether dupilumab treatment can cause, accelerate, or unmask cutaneous T-cell lymphoma.

Dupixent is a monoclonal antibody administered by subcutaneous injection that blocks signaling by interleukin-4 and interleukin-13 through the IL-4 receptor alpha subunit.

Researchers have examined whether reported cases represent dupilumab associated lymphoma, progression of preexisting disease, or cutaneous lymphoma unmasking in patients whose early CTCL symptoms were initially diagnosed as atopic dermatitis.

Published studies have evaluated CTCL incidence, adverse-event reporting patterns, clinical characteristics, and treatment outcomes after Dupixent exposure.

Laboratory analyses have also examined IL-13 receptor expression and other changes in the skin that may help explain a possible biological mechanism.

These findings identify an association that requires further investigation, but they do not establish that Dupixent causes CTCL in every patient diagnosed after treatment.

Several published studies and data analyses have examined these questions, including:

• Mandel et al. retrospective cohort study: Researchers compared 19,612 patients with atopic dermatitis who received dupilumab with 19,612 matched patients who did not. The dupilumab group had a reported 4.59-fold relative risk of CTCL, and 34 of the 55 CTCL diagnoses in that group occurred within one year after treatment began.
• Hasan et al. retrospective cohort study: This Journal of the American Academy of Dermatology study reported an odds ratio of 4.10 for CTCL among patients with atopic dermatitis treated with dupilumab compared with patients who did not receive the drug. The researchers did not identify a similar association for the other cutaneous or lymphoid malignancies evaluated.
• Stuver et al. retrospective matched cohort study: Researchers compared 27 patients diagnosed with mycosis fungoides after dupilumab exposure with 27 matched patients who had not received the drug. The study examined clinical characteristics, disease stage, and treatment outcomes rather than the incidence of CTCL among all Dupixent users.
• Cabrera-Perez et al. FAERS and immunotranscriptomic analysis: Researchers identified 181,575 dupilumab-associated adverse-event reports submitted from 2017 through the fourth quarter of 2023, including 606 neoplasm reports and 178 reports involving CTCL. Dupilumab had a CTCL proportional reporting ratio of 30.0 compared with other medications in FAERS, with the strongest reporting signal found among men aged 45 to 65.
• Cabrera-Perez et al. transcriptomic analysis: The same publication examined bulk and single-cell RNA-sequencing data to evaluate possible biological mechanisms involving IL-4 and IL-13 signaling. The findings identified differences in IL-13 receptor expression, including changes involving keratinocytes, but did not establish that dupilumab directly causes malignant T-cell transformation.

These studies have identified statistical associations, adverse-event signals, and possible biological mechanisms that will likely be examined in the Dupixent MDL.

Retrospective databases and FAERS reports cannot independently determine whether Dupixent caused an individual patient’s cancer because they may be affected by diagnostic overlap, preexisting CTCL, surveillance bias, and incomplete reporting.

Each lawsuit will require patient-specific evidence concerning Dupixent exposure, the timing of symptoms and biopsies, pathology findings, disease progression, and alternative explanations for the CTCL diagnosis.

How Does Dupixent Allegedly Cause CTCL?

Dupixent blocks signaling from interleukin-4 and interleukin-13 through the IL-4 receptor alpha subunit as part of its therapy for atopic dermatitis and other inflammatory conditions.

Plaintiffs allege that altering these immune pathways may affect the environment in which malignant T cells survive and multiply, contributing to CTCL development in susceptible patients.

One proposed explanation is that blocking IL-4 receptor alpha leaves more IL-13 available to bind to receptors expressed by CTCL cells, potentially stimulating preexisting malignant clones or accelerating an undiagnosed disease.

Researchers have also identified changes in IL-13 receptor expression in keratinocytes and other skin cells, although the underlying mechanisms remain under investigation.

Another theory is that Dupixent does not create lymphoma but suppresses eczema-like inflammation that had concealed early CTCL, allowing the disease to become more clinically apparent after treatment begins.

A retrospective cohort study found that 34 of 55 Dupixent users who developed CTCL received their diagnosis within one year of starting treatment, while a systematic review reported an average diagnosis time of 7.8 months after initiation.

These findings have led researchers to examine whether dupilumab use is associated with increased risk of CTCL occurrence through disease acceleration, cutaneous lymphoma unmasking, or delayed recognition of symptoms initially attributed to atopic dermatitis, but current evidence does not establish a single confirmed causal pathway.

The Dupixent MDL primarily includes claims involving cutaneous T-cell lymphoma diagnosed after a patient initiated dupilumab treatment.

These cases often involve people who were originally treated for atopic dermatitis, eczema, asthma, or another inflammatory condition before receiving a lymphoma diagnosis.

The current proceeding focuses on CTCL and its recognized subtypes rather than every form of lymphoma reported after Dupixent use.

Whether a significant difference exists between patients exposed to Dupixent and comparable patients who did not receive the drug remains one of the scientific questions being examined in the litigation.

Medical conditions currently associated with claims in the Dupixent MDL include:

• Cutaneous T-cell lymphoma
• Mycosis fungoides
• Sézary syndrome
• Preexisting or undiagnosed CTCL that allegedly progressed during Dupixent treatment
• CTCL initially misdiagnosed as atopic dermatitis, eczema, or another inflammatory skin condition
• Other T-cell lymphomas that may be considered for transfer based on the allegations and future court order

Filing a Dupixent lawsuit begins with a review of the patient’s prescription history, medical records, biopsy results, pathology reports, and treatment timeline.

A lawyer will examine when Dupixent use began, which condition it was prescribed to treat, when symptoms changed or worsened, and when the CTCL diagnosis was confirmed.

The claim must also identify the manufacturers or related defendants believed to be responsible and explain how inadequate warnings or other alleged misconduct contributed to the injury.

Federal cases involving the same core allegations may be transferred into the Dupixent MDL for coordinated pretrial proceedings.

Each claimant must still establish individual causation, damages, and compliance with the applicable statute of limitations.

Recoverable damages may include medical expenses, lost income, pain and suffering, reduced quality of life, and wrongful death losses when applicable.

Because filing deadlines vary by state and can depend on when the injury was discovered, potential claimants should have their case reviewed as soon as possible.

Gathering Evidence in Dupixent Cases

Evidence in Dupixent cases must establish the patient’s treatment history, CTCL diagnosis, disease progression, and resulting losses.

A complete medical timeline can also show whether lymphoma symptoms were initially attributed to atopic dermatitis or another inflammatory condition before further testing was ordered.

Lawyers may use the following records and materials to evaluate causation, warning allegations, and damages:

• Prescription and pharmacy records showing when Dupixent treatment began and ended
• Dermatology records documenting atopic dermatitis, eczema, rashes, plaques, itching, and other skin symptoms
• Medical notes describing whether symptoms improved, persisted, changed, or worsened during treatment
• Skin biopsy results and pathology reports confirming CTCL, mycosis fungoides, or Sézary syndrome
• Records of multiple biopsies, pathology reviews, and specialist referrals
• Oncology records showing disease stage, treatment, prognosis, and progression
• Photographs documenting visible skin changes over time
• Laboratory results, imaging studies, and blood testing related to the lymphoma diagnosis
• Records showing the condition for which Dupixent was prescribed
• Communications with prescribing doctors about side effects or treatment response
• Employment records documenting lost income or reduced earning capacity
• Medical bills, travel expenses, and other treatment-related costs
• Death certificates, funeral expenses, and family records in wrongful death cases
• Expert opinions addressing diagnosis, causation, warnings, and alternative explanations

Potential Compensation in a Dupixent Lawsuit

Potential compensation in a Dupixent lawsuit depends on the severity of the lymphoma diagnosis, the cost and duration of treatment, the effect on the patient’s ability to work, and the broader impact on daily life.

Lawyers assess damages by reviewing medical records, billing statements, employment history, expert opinions, and evidence showing how the diagnosis changed the patient’s health and financial circumstances.

Future losses may require testimony from doctors, economists, vocational specialists, or life-care planners to estimate ongoing treatment needs, reduced earning capacity, and long-term physical limitations.

Attorneys use this evidence to calculate the full value of the claim and advocate for compensation that accounts for both economic losses and personal harm.

Damages in a Dupixent lawsuit may include:

• Past and future medical expenses
• Costs of chemotherapy, radiation, immunotherapy, or other cancer treatment
• Expenses for specialist care, testing, monitoring, and follow-up treatment
• Lost wages and missed work
• Reduced future earning capacity
• Pain and suffering
• Emotional distress
• Loss of quality of life
• Permanent disability or physical impairment
• Travel and lodging expenses for medical care
• Prescription medication and supportive care costs
• Household assistance and caregiving expenses
• Funeral and burial expenses
• Wrongful death damages for surviving family members
• Loss of companionship, support, and services

TorHoerman Law is investigating claims from people who used Dupixent and were later diagnosed with cutaneous T-cell lymphoma or another qualifying T-cell lymphoma.

Our attorneys review prescription records, dermatology notes, biopsy results, pathology reports, treatment history, and evidence of financial and personal losses to determine whether a claim may be supported.

We also examine whether the diagnosis followed persistent or worsening symptoms that were initially treated as atopic dermatitis, eczema, asthma, or another inflammatory condition.

If you or a loved one developed CTCL after Dupixent treatment, contact TorHoerman Law for a free case evaluation.

We handle these cases on a contingency fee basis, so there are no upfront costs, and attorney fees are collected only if compensation is recovered.